Szili, Dániel <br/><br/>
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.  [electronic resource] 

 -  mAbs   
 - 991-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1942-0870 
<br/><br/><label>Standard No.: </label>10.4161/mabs.28841  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--immunology<br/>Antigens, CD19<br/>B-Lymphocytes--immunology<br/>Cell Proliferation--drug effects<br/>Cytokines--immunology<br/>Female<br/>Humans<br/>Immunity, Innate--drug effects<br/>Immunoglobulin G--immunology<br/>Immunosuppressive Agents--immunology<br/>Lymphocyte Activation--drug effects<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Middle Aged<br/>Receptors, Antigen, B-Cell--immunology<br/>Receptors, IgG--antagonists & inhibitors<br/>Toll-Like Receptor 9--antagonists & inhibitors